Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 6/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22905342 | 0.83 | MAPT (0.46) | FAAHCTNNB1WNT3AHTTNPSR1 | |
| SCHEMBL9838828 | 0.83 | NOS2 (0.42) | PDE2AROCK2FAAHNOS2CTNNB1 | |
| SCHEMBL8184134 | 0.82 | CTNNB1 (0.42) | PDE2AROCK2FAAHNOS2CTNNB1 | |
| SCHEMBL18656445 | 0.81 | KDM4E (0.41) | PDE2AROCK2FAAHNOS2CTNNB1 | |
| SCHEMBL2663369 | 0.79 | CTNNB1 (0.41) | FAAHCTNNB1WNT3AHTTNPSR1 | |
| SCHEMBL3750115 | 0.78 | ADH1B (0.42) | PDE2AROCK2FAAHNOS2CTNNB1 | |
| SCHEMBL2537768 | 0.77 | CYP19A1 (0.43) | ROCK2FAAHCTNNB1WNT3AHTT | |
| SCHEMBL8367478 | 0.76 | CNR1 (0.40) | PDE2AFAAHCTNNB1WNT3AHTT | |
| SCHEMBL18571251 | 0.76 | KIF11 (0.43) | ROCK2FAAHCTNNB1WNT3AHTT | |
| SCHEMBL22517184 | 0.76 | ALDH1A1 (0.37) | HTTSLC6A4LOXL2MAPK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | PDE2A 1640/4885ROCK2 1161/4885FAAH 4587/4885 |
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | PDE2A 334/4885ROCK2 2789/4885FAAH 3336/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | PDE2A 856/4885ROCK2 771/4885FAAH 4697/4885 |
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | PDE2A 3273/4885ROCK2 507/4885FAAH 1635/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | PDE2A 856/4885ROCK2 771/4885FAAH 4697/4885 |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | PDE2A 2367/4885ROCK2 3515/4885FAAH 1713/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | PDE2A 3407/4885ROCK2 557/4885FAAH 1137/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | PDE2A 3407/4885ROCK2 557/4885FAAH 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.